DANA-FARBER CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 13
- Registration Number
- NCT03187262
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Ear Acupuncture During Chemotherapy Infusion for Breast Cancer, a Feasibility Study
- Conditions
- Breast Cancer
- Interventions
- Device: Acupuncture
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 26
- Registration Number
- NCT03170648
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT03170206
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
- Conditions
- OligodendrogliomaGangliogliomaGlioblastomaPylocytic/Pylomyxoid AstrocytomaBrain TumorGliomaMalignant Glioma of BrainAstrocytomaMalignant AstrocytomaMixed Oligo-Astrocytoma
- Interventions
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 62
- Registration Number
- NCT03152318
- Locations
- 🇺🇸
Johns Hopkins University Medical Center, Baltimore, Maryland, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Palbociclib After CDK and Endocrine Therapy (PACE)
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 220
- Registration Number
- NCT03147287
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
- Conditions
- Prostate Cancer
- Interventions
- Radiation: Salvage radiation
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 345
- Registration Number
- NCT03141671
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.
- Conditions
- LymphomaCancer SurvivorshipAutonomic Imbalance
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 23
- Registration Number
- NCT03137537
- Locations
- 🇺🇸
Boston Children Hospital, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Cyclophosphamide and Alemtuzumab In Lymphoma
- Conditions
- Non Hodgkin LymphomaHigh-grade B-cell LymphomaDiffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT03132584
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
- Conditions
- ALK-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Thyroid Cancer
- Interventions
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT03131206
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT03130439
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States